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We determined the response of peripheral blood mononu-
clear cells from patients with bullous pemphigoid and nor-
mal subjects to synthetic pep tides encoded by BPAG 1. Pe-
ripheral blood mononucl~ar cells from patients and no~mal 
subjects were cocultured m the presence of 15 - 22-ammo-
acid -long amphipathic and hydrophilic peptides selected 
from the BPAG 1 sequence. Seven of 10 patients (70%) with 
bullous pemphigoid had an increased response of peripheral 
blood mononuclear cells (> 3.25/106 cells) when cultured 
with amphipathic sequences encoded by BPAG1 compared 
to 3 of 10 (30%) normal subjects. Peripheral blood mononu-
clear cells from 3 of 15 (20%) patients and 3 of 15 normal 
subjects (20%) demonstrated an increased response when 
cultured with hydrophilic peptides. Pep tides associated with 
an increased peripheral blood mononuclear cell response in 
T he autoimmune blistering disease bullous pemphigoid (BP) is characterized in part by the presence of circu-lating and tissue bound antibasement membrane auto-antibodies. Indirect evidence suggests that T cells may play a role in the induction and maintenance of au-
toantibody production in this disease. First, autoantibodies in BP are 
directed against multiple epitopes on the 180- and 230-kD BP anti-
gens, consistent with a T -cell- mediated, antigen-driven immune 
response [1- 5]. Second, soluble IL-2 receptor levels in the serum of 
patients with BP are elevated when compared to normals, compati-
ble with T-cell activation [6]. Third, peripheral blood lymphocytes 
from patients with BP have been demonstrated to bear an increased 
frequency of CD4-positive cells, the phenotype associated with T 
hel per jinducer cells, and markers ofT-ceil activation, including the 
antigens HLA-DR and the IL-2 receptor [6,7]. In addition, 
CD4-positive cells, and LFA-l-bearing lymphocytes have been 
detected in the skin of patients with BP adjacent to the basement 
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patients with bullous pemphigoid were adjacent to regions of 
BPAG 1 recently demonstrated to contain epitopes recog-
ni~ed by circulatin~ a~toantibodies in the sera of patients 
with bullous pemphigOld. Increased peripheral blood mono-
~uclear ~ell responses wer~ m?re ~ommonly observed in pa-
tients With bullous pemplugOld with generalized disease and 
those who had their: disease .for longer than 2 months (p < 
0.05). The observatlOn that mcreased duration and general-
ized disease was associated with increased peripheral blood 
mononuclear cell responses to peptides encoded by BPAG 1 
supports the hypothesis that responses to BPAG1 may occur 
as a consequence of ongoing inflammation at the basement 
membrane. Key words: bullous pemphigoid/BPAG1 / T-cell epi-
topes. ] Invest Dermatol1 03:73 - 77} 1994 
membrane [8,9]. Finally, the cytokines IFN-y and interleukin 5 
have been detected in the blister fluid of patients with BP, suggest-
ing a role for T cells in blister formation in BP [8,10]. 
To evaluate further the role of T cells in patients with BP, we 
determined the response of peripheral blood mononuclear cells 
(PBMe) (expressed as the number of proliferating PBMCj106 
PBMe), when ~ultured 111 the pr~sence of synthetic pep tides en-
coded by the major 2~0-kD ~P antigen, BPAG 1. We hypothesized 
that PBMC from patients With BP would have an increased number 
of PBMC that respond to specific regions of BPAG 1. PBMC from 
patients with BP and controls were cultured with synthetic peptides 
from amphipathic and hydrophilic regions of BPAG1, and the 
PBMC response was determined based on limiting dilution analysis 
and the Poisson distribution. An increased PBMC response, as de-
fined by a response greater than 3.25/106 cells, was observed in 7 of 
10 (70%) patients with BP, and 3 of 10 (30%) normal controls 
cultu~ed wit~ amphipathic peptides . Sequences encoded by BPAG 1 
associated With .111creased precursor ~requency localized to regions 
ofBPA,<~ 1 pr.oxllnal to recently des~nbed epitopes for autoantibody 
recogmtlOn, mcludmg sequences adjacent to the amino and carboxy 
terminal ~~ds of t~e coile~-coil region of the molecule [4]. 
In addition, patients With BP who demonstrated an increased 
PBMC response whe.n cultured with synthetic pep tides encoded by 
BPAG1 were more Itkely to have generalized disease, and to have 
had BP for longer than 2 months (p < 0.05). The demonstration of 
increased PBMC responses in patients with generalized BP and 
those who had thei~ disease for longer than 6 weeks supports the 
hypothesIs that the Immune response against the 230-kD BP AG 1 
may arise in patients with bullous pemphigoid secondary to inflam-
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Table I_ Synthetic Peptides 
Location Amphipathic 
Peptide Sequence (Amino Acid) Score 
Amphipathic peptides 
T1 KTVEEVQKTL 2120-2136 42.1 
NKFLTKA 
T2 KFKQSAEEFRK 1745-1765 29.5 
KMEKLMESK 
T3 ITQLEKEVNVC 708-727 51.3 
KQYYQELLK 
T4 EKLKKELERLK 784-803 60.7 
DDLGTITNK 
T5 QIDNRLRDLEG 951-967 72.1 
IGKSLK 
T6 PLDDWIQQVET 975-989 72.1 
TQRK 
T7 QSKMDECQKY 1019-1037 45.4 
AEQYSATVK 
T8 IQRLNEELEKS 1555-1574 55.1 
NECAEMLKQ 
Hydrophilic peptides 
P1 SNTRVFPNPNN 2287-2302 <7.0 
LQALY 
P3 KST AKDCTFKP 1870-1898 < 7.0 
DFEMTVKE 
P4 WTQEPQPLEEK 1914-1931 7.4 
WQHRVVE 
P5 ELNASKEEKRR 1688-1704 < 7.0 
GEQKVQL 
P6 ICQRKSDHLKE 1522-1480 <7.0 
QFEKSHEQ 
mation and disruption at the basement membrane, and may be rele-
vant in perpetuating the immune response, but may not be the 
initiating event in the pathogeneSIS of the disease [11]. 
MATERJALS AND METHODS 
Patients Fifteen patients with BP were studied during the course of this 
study; however, not every patient was assayed against each of the peptides. 
Preliminary studies focused on evaluating the response of PBMC from pa-
tients and controls to hydrophilic peptides. Additional pep tides were syn-
thesized during the course of the study and PBMC assayed to peptides as 
available. Given the large number of replicate wells utilized (see below), 
there were limits on the numbers of peptides screened per subject. 
Thirteen patients had generalized BP involving the skin but sparing mu-
cosal surfaces. Two patients assayed for response to amphipathic peptides 
had localized BP with blistering confined to the lower legs. All patients, 
including those with localized BP, had clinical, histologic, and immunoflu-
orescent features of bullous pemphigoid including the presence of a subepi-
dermal blistering disease on routine histology and linear deposits of C3 and 
immunoglobulin (Ig)G on direct immunofluorescence of perilesional skin 
biopsies. Indirect immunofluorescence (lIF) studies on normal human split 
skin revealed circulating IgG that bound to the epidermal side of salt-split 
skin (circulating anti-basement membrane antibody titer > 1 : 40) in all pa-
tients with BP. 
All patients had active blistering disease at the time of the study. Eight 
patients were on oral prednisone for control of their disease, but none were 
on immunosuppressants. Control subjects were healthy volunteers with no 
history of skin disease or autoimmune disorders, and no detectable circulat-
ing autoantibodies on lIF. On the day of the assay, 40 ml of whole blood was 
drawn by venipuncture from patients and control subjects using heparinized 
syringes. 
Synthetic Peptides PBMC from patients and controls were assayed 
against 14 nonoverlapping synthetic peptides (Table I). Amphipathic pep-
tides included eight synthetic peptides ranging in size from 15-20 amino 
acids (AA) in length. These peptides were selected based on a T-cell recogni-
tion paradigm developed by Berzofsky and co-workers that predicts T-cell 
epitopes within amphipathic regions of the molecule [12,13]. Amphipathic 
regions are ex helical domains with polar and apolar faces on opposite sides of 
the helix. It is postulated that the hydrophilic and hydrophobic domains on 
the peptide interact with the T-ccll receptor and MHC Class II molecule, 
respectively (12,14]. The amphipathic peptides in Table I were selected for 
synthesis based on the above paradigm using the computer modeling pro-
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gram, AMPHI, which predicts an amphipathic score based on sequence 
analysis [12J. 
The hydrophilic peptides include five synthetic pep tides ranging from 17 
to 22 AA long, encoded with the BPAG1 cDNA sequence, which were 
selected for synthesis based on an antibody recognition construct for hydro-
philicity [15). These pep tides have been previously assayed for reactivity 
with IgG in the serum of patients with BP and normal blood bank donors by 
enzyme-linked immunosorbent assay (ELISA) [2). 
Synthetic peptides selected for synthesis were representative of all regions 
of BPAG 1, with the exception of the most amino terminal region (Fig 1). 
Synthetic peptides were selected to encompass regions of the molecule pre-
viously determined to include regions of antibody reactivity [3,4). 
Peptides were commercially synthesized, cleaved, desalted, and analyzed 
by high-performance liquid chromatography (HPLC) (Immunodynamics, 
La Jolla, CAl. Lyophilized peptides were dissolved in sterile phosphate-buf-
fered saline (PBS), dialyzed extensively against sterile PBS, dispensed in 
aliquots, and stored at -70· C. Each peptide was assayed for cellular toxicity 
by co-culture with PBMC from normal donors, and for the inhibition of 
normal PBMC stimulation by phytohemagglutinin (PHA) and were deter-
mined to be nontoxic (data not shown). 
Cell Culture PBMC obtained from patients and controls were separated 
from heparinized whole blood by density gradient centrifugation using LSM 
(Organon Teknika, Durham, NC) . Cells recovered from density gradient 
centrifugation were washed three times in RPMI and resuspended in cold 
RPMl. Isolated PBMC were cultured in the presence of synthetic peptides, 
mitogen controls, or media alone. Cells were plated at 10' cells/well in 
200 III RPMl with 15% heat-inactivated All-negative serum (Gibco) and 
cultured in round-bottom wells of 96-well tissue culture plates at 5% CO2, 
37"C. Mitogen controls included PHA (1-10 Ilg/ml, Burroughs-Well-
come, Research Triangle Park, NC) and OKT3 (1: 10,000-1 : 100,000 
dilution in 5% heat-inactivated fetal calf serum). 
PBMC incubated with synthetic pep tides and media were assayed in repli-
cates of 16 wells each (hydrophilic peptides) or 20 wells each (amphipathic 
peptides) at 50 Ilg/ml for 6 d. Cultures were then labeled with tritiated 
thymidine (NEN, Dupont, Boston, MA) for 16 h and the cells harvested. 
Cells incubated with mitogen controls were assayed in replicates of four 
wells per dilution for 3 d (PHA) and 4 d (OKT3) and labeled for 4 h with 
tritiated thymidine. Uptake of tritiated thymidine was determined for each 
well by harvesting the wells on glass fiber filter mats (PHD Cell Harvester, 
Cambridge, MA) and liquid scintillation counting (Beckman Instruments, 
FullterOl1, CAl. 
Determination ofPBMC Response The response ofPBMC was deter-
mined by calculating the number of proliferating cells per million PBMe 
based on limiting dilution analysis and the Poisson distribution [16). The 
low frequency of PBMC specific for T-cell peptides is best described using 
Poisson sampling statistics and a large number of replicate cultures [16,17]. 
Data from patients with BP and normal subjects were analyzed to deter-
mine the Poisson mean for each peptide, that is, the mean number of precur-
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Figure 1. Schematic representation of BPAG 1, indicating the coiled-coil 
region and synthetic peptide constructs. Amphipathic peptides are desig-
nated TI-T8; hydrophilic peptides are designated Pl, P3-P6. 
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sors per culture (105 cells/well) , from which we calculated the response per 
106 cell s. The Poisson mean was calculated for each patient and normal 
subject by first ranking the counts per minute (cpm) of all wells and deter-
mining the background mean and standard deviation of nonproliferating 
wel ls, including both nonstimulated (cells + media) and any stimulated 
(cells + peptide) wells with low cpm counts. The mean and standard devia-
tion of the nonproliferating wells was determined. The upper limit of the 
normal range of proliferation was then determined by calculating the mean 
plus 3.29 times the standard deviation to ensure that not more than 0.1 % of 
"true negatives" will be above this upper limit [1 7]. Wells with cpm above 
the upper limits of normal were scored as positive. The Poisson mean was 
calculated based on the number of nonproliferating wells observed from 
among the total number of wells tested (Poisson mean = log.,[total wells/ 
negative wells]) . The PBMC response for each specific peptide was then 
calculated from the Poisson mean by dividing the Poisson mean by the 
number of PBMC plated in each replicate culture. The data are expressed as 
the response per 106 ce ll s. 
Statistical Analysis The paired response of patients with BP and normal 
subjects was analyzed using McNemar's test for correlated proportions. The 
frequency of an increased response between BP patients and controls was 
compared using Fisher's exact test. The frequency of an increased response 
from all assays was compared between BP patients and controls using the 
Chi-square test. Statistical analysis was performed using a statistical software 
package (SAS, Cary, NC). 
RESULTS 
Peripheral Blood Mononuclear Cells From Patients With BP 
and Normal Subjects Poliferate When Co-cultured with 
pHA and OKT3 PBMe from patients with BP and normal sub-
jects proliferate when co-cultured in the presence of the T-cell 
mitogen PHA, or OKT3, a monoclonal antibody specific for the 
eD3 antigen of the T-cell receptor. (PBMe response for PHA 
was> 10/106 cells from patients with BP and normal subjects; 
PBMe response for OKT3 was> 10/106 cells from patients with 
BP and normal subjects.) There was no significant difference in the 
proliferative response of patients with BP treated or not treated with 
prednisone, as shown previously [18]. 
Peripheral Blood Mononuclear Cells From Patients With BP 
Demonstrate an Increased Response to Amphipathic Pep-
tides Encoded by BPAGI The frequency of the PBMe re-
sponse, expressed as the number of proliferating cells/l06 PBMe 
from patients with BP and normal subjects was determined for eight 
pep tides synthesized frOl~ a~nphipathic regions. An increased 
PBMe response was seen 111 mne assays measunng the response to 
individual peptides in patients with BP and four assays in normal 
subjects out of a total of 90 paired assays (Fig 2A). Seven of 10 
patients with BP (70%) and 3 of 10 normal subjects (30%) demon-
strated increased PBMe responses (frequency of responding 
PBMe> 3.25/106 cells) when cultured with amphipathic peptides 
encoded by BPAG 1 (Table II) . The response in BP patients was not 
significantly different from the response of controls (7 of 1 0 versus 3 
of 10; p = 0.089, Fisher's exact test) . Using nonparametric analysis, 
no statistically significant difference in paired reactivity between 
patients with BP and normal subjects was demonstrated (McN e-
mar's paired test for correlated proportions). 
The presence of an increased PBMe response in BP patients to 
amphipathic peptides was more often detected in patients with gen-
eralized BP and in those with BP for longer than 6 weeks. Seven of 
eight patients with generalized BP demonstrated an increased re-
sponse to one or more amphipathic peptides whereas neither of the 
fWO patients with localized BP demonstrated an increased response 
to any of the amphipathic peptides. The increased response of pa-
tients with generalized BP is significant when compared to the 
controls (seven of eight BP patients versus 3 of 10 controls; p = 
0.023, Fisher's exact test). 
All six patients with a history of blistering for longer than 6 weeks 
at the time of the study demonstrated an increased response to one or 
more amphipathic peptides. The presence of an increased PBMe 
response rate correlated with disease duration for longer than 6 
weeks (6 of 6 BP patients versus 3 of 10 controls; p = 0.01, Fisher's 
exact test). One of the four patients studied during the acute phase of 
Figure 2. PBMC from patients with BP demonstrate an increased prolifer-
ative response to amphipathic peptides (A) but not to hydrophilic peptides 
(B) encoded by BPAG I. The PBMC response (number of responding cells/ 
106 PBMC) for patients with BP (e) a.nd control subjects (0) for each 
synthetic peptide are graphed. PBMC from patients and controls were cul-
tured for 7 d in the presence of the designated synthetic peptide and the 
proliferation ofPBMC was measured. The data are expressed as the number 
of proliferating cells/l 06 PBMC. Each data point represents the response of a 
patient or control to the pel'tide listed on the X axis. A) PBMC from patients 
and controls were cultured 111 the presence of amphipathic synthetic peptides 
TI-T8. An increased PBMC response was seen in nine assays for seven 
patients with BP and in four assays for three control subjects. B) PBMC from 
patients and controls were cultured in the presence of five non-overlapping 
hydrophilic peptides, Pl and P3-P6. An increased PBMC response was seen 
in four assays for three patients with BP and in three assays for three control 
subjects. 
their illness (< 6 weeks after the onset of blistering) demonstrated 
an increased response to an amph ipathic peptide; however, the ma-
jority of these patients (three of four) did not demonstrate an in-
creased response to any of the peptides encoded by BP AG 1. 
Six of the patients with BP, all of whom had generalized disease, 
and disea~e for longer .than 6 weeks, were on prednisone. PBMe 
from all SIX of these patIents d~monstrated an increased proliferative 
response to ampll1pathl~ peptldes whereas only one of four patients 
not on oral corticosterOIds demonstrated an increased proliferative 
response. Thus, the admul1stration of oral corticosteroids was asso-
ciated with an increased PBMe response to BP AG 1 amphipathic 
peptides. However, this association may be due to sample bias in that 
patients with generalized disease and active blistering for longer 
than 6 weeks were all receiving prednisone at the time of the study. 
Some Patients With BP and Controls Have an Increased 
PBMC Proliferative Response to Hydrophilic Peptides En-
coded by BPAGI Increased PBMC responses to hydrophilic 
pep tides were observed in four assays with PBMe from patients 
with BP and three assays with PBMC from normal controls of 37 
paired assays (Fig 2B). These increased PBMe responses occurred in 
three patients with BP, all of whom responded to at least one am-
phipathic peptide, and three controls. Three of fifteen patients 
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Table II. Number (Percent Responding) of BP Patients and 
Normal Subjects Demonstrating an Increased Precursor 
Frequency to Synthetic Peptides Encoded by BPAGla 
DP Normal Number 
Peptide Patients' Subjects' Tested 
Amphiphatic peptides 
0 0% 0 0% 15 T1 
T2 0 0% 0 0% 15 
T3 1 10% 0 0% 10 
T4 1 10% 0 0% 10 
T5 2 20% 0 0% 10 
T6 3 30% 2 20% 10 
T7 1 10% 1 10% 10 
T8 1 10% 0 0% 10 
Total responseb 7 70% 3 30% 
Hydrophilic peptides 
P1 1 7% 0 0% 7 
P3 3 20% 2 13% 15 
P4 0 0% 1 14% 7 
P5 0 0% 0 0% 4 
P6 0 0% 0 0% 4 
Total response 3 20% 3 20% 
• PBMC from patients with BP and normal subjects were cultured in the presence of 
amphipathic and hydrophi lic peptides for 7 d and the presence of all increased response 
(> 3.25 proliferating cells/10' cells) determined for each patient and control. The 
number (percent responding) of patients and controls who demonstrated an increased 
PBMC response rate is shown. 
• Some patients and controls demonstrated an increased response to more than one 
peptide. 
' Number of patients or normal subjects with precursor frequency > 3.25/106 cells. 
(20%) with BP and 2 of 15 normal subjects (11 %) demonstrated an 
increased frequency of response to the hydrophilic peptide P3 
(Table II). All three patients with an increased response to the am-
phipathic'peptide T6 also responded to the hydrophilic peptide P3. 
Of controls, two ofl0 (20%) responded to T6 and two of 15 (11 %) 
responded to P3, but none responded to both. Peptides T6 and P3 
are not contiguous and do not share sequence homology (Fig 1). 
The proliferative response of PBMC was elevated in one BP 
patient to peptide PI, and in one control patient to P4 but no other 
responses to hydrophilic peptides were seen (Fig 2B). There was no 
significant difference in the response of patients with BP when 
compared to controls when cultured with hydrophilic peptides, and 
no correlation with severity or duration of disease was noted. 
Some Patients With BP Demonstrate Increased Frequency of 
PBMC Proliferative Responses to More Than One Peptide 
Encoded by BPAGI Among the seven patients with BP who 
responded, there were a total of 13 assays in which the frequency of 
PBMC response was elevated: three patients demonstrated an in-
creased response to two peptides and one patient demonstrated an 
increased response to four peptides. Among the six controls with 
increased responses, five patients responded to one peptide and one 
patient demonstrated an increased response to two peptides, for a 
total of seven assays in which an increased response was detected. 
There is no statistically significant difference in the number of 
assays demonstrating increased response between patients with BP 
and controls (p = 0.244, Chi-square). 
Increased PBMC Proliferative Responses Occur With Am-
phipathic and Hydrophilic Peptides Encoded Near the 
Coiled-Coil Region of BPAGI In evaluating the response to 
individual peptides, none of the 15 patients or 15 controls demon-
strated an increased response to the amphipathic peptides Tl or T2 
encoded w ithin the carboxyl domain and the amino-end of the 
coiled-coil region, respectively (Fig 1). Increased PBMC prolifera-
tive responses were seen to the amphipathic peptides T3 - T8 and 
the hydrophilic peptides PI and P3 in patients with BP. These 
peptides are encoded by sequences at the carboxyl end of the coiled-
coil region (T3 - T7), the carboxyl third of the coiled-coil region 
(T8), and adjacent to the coiled-coil region (P3) . 
Peptides at the carboxyl end of the coiled-coil region (T3 - T7) 
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were associated particularly with an increased frequency of PBMC 
response; all seven patients who demonstrated an increased PBMC 
response reacted with one or more peptides within this region. 
Similarly, each of the three normal subjects who demonstrated an 
increased response also reacted to synthetic pep tides encoded within 
this region (T6 - T7). These synthetic peptides span an 886-AA 
region at the proximal third of the molecule, including the amino 
terminal end of the coiled-coil region (Fig 1). 
DISCUSSION 
Since the cloning of the gene for BPAG 1, significant interest has 
focused on identifying the site or sites on the antigen relevant in the 
pathogenesis of the autoimmune blistering disease bullous pemphi-
goid. Previous studies have focused on identifying regions of anti-
body recognition using either small synthetic peptides or fusion 
proteins derived from human or mouse BPAG 1 cDNA. Immunoas-
says employing both immunoblot and ELISA have demonstrated 
the presence of an antibody binding epitope(s) within the carboxy 
terminal domain of the molecule [1 - 3]. Additional sites of circulat-
ing antibody reactivity have been identified recently proximal to the 
amino and carboxy terminal regions of the coiled-coil region by 
immunoblot using fusion proteins encoded by these regions of 
BPAG1 [4] . These investigations have demonstrated that circulat-
ing IgG in the sera of some patients with BP reacts with multiple 
epitopes, suggesting that autoantibodies in this disease arise as a 
consequence of a T-cell-mediated antigen-driven process. 
The present study focuses on the potential role of T cells in the 
pathogenesis of BP, as reflected by an increased frequency of 
PBMC, which demonstrate a proliferative response when cultured 
in the presence of synthetic pep tides encoded by BPAG 1. T cells 
comprise 70% of the PBMC population and proliferate in the pres-
ence of antigen and antigen-presenting cells. Assaying the prolifer-
ative response of PBMC to synthetic pep tides encoded by target 
antigens has been used in other autoimmune diseases to map T-cell 
epitopes [19,20]. 
Seven of 10 (70%) patients with BP had an increased frequency of 
PBMC that proliferate when cultured in the presence of amphi-
pathic peptides encoded by BPAG1 as compared to 3 of 10 (30%) 
controls. The presence of this increased PBMC response in patients 
with BP was associated with the presence of generalized disease, 
with the duration of the disease greater than 6 weeks. The presence 
of an increased PBMC response in patients with generalized disease, 
but not in those with localized disease, suggests that there may be 
some differences in the pathogenesis of localized and generalized 
BP, although autoantibodies from patients with localized BP have 
been demonstrated to react with the 230-kD BPAGI [21]. 
Although there are a limited number of patients in this study, the 
absence of a detectable increased PBMC response against any of the 
synthetic peptides in patients with blistering for less than 6 weeks 
duration supports the hypothesis that the immune response against 
the 230-kD BPAG 1 may arise during the course of disease, and may 
not be relevant in initiating the disease [11]. The development of 
add itional sites of reactivity on a target antigen or antigens during 
the course of an immune response, a process known as determinant 
spreading, has been noted in other autoimmune diseases, particu-
larly multiple sclerosis [22]. 
No significant difference in reactivity was seen in patients or 
controls to hydrophilic peptides encoded by BP AG 1. Increased re-
sponses to hydrophilic peptides were seen in 3 of 15 (20%) patients 
and 3 of 15 controls (20%). 
Among both patients with BP and normal subjects who demon-
strated an increased PBMC response, synthetic peptides associated 
with increased responses were restricted to regions of the molecule 
associated with antibody reactivity , including domains adjacent to 
the amino (T3 - T7) or carboxy end (T8 ,P3) of the coiled-coil re-
gion of the molecule. Fusion proteins generated from these regions 
are recognized on immunoblot by sera from 70% (amino end) and 
33% (carboxy end) of patients with BP [4]. All seven patients who 
reacted with the amphipathic peptides reacted with one or more 
pep tides encoded at the amino end of the coiled-coil region. Thus, 
increased precursor frequencies of PBMC from patients with 
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BP co-localized .n.ear regions previously recognized as relevant in 
ntibody recogmtlon. 
a These data support recent investigations that have demonstrated 
that T-cell epitopes tend to ocur in close proximity to B-cell epi-
topes [23 - 25]. The demonstration of proximity of mapped epitopes 
for B- and T-cell responses has suggested a conformational require-
ment for B- and T-cell epitopes in the generation of an immune 
response. An alternative hypothesis to explain B- and T -cell epitope 
i"nkage has been suggested by Barnett et ai, who postulate that a~tigen-specific B cells may playa role in the selection of the pe-
ripheral T-cell repertoire [26] . If this hypothesis is true, then the 
increased PBMC response in patients with BP specific for synthetic 
eptides encoded by BPAG 1. may be a consequ~nce of the autoim-~une disease and not an II1ltlatmg factor. TI1lS latter hypothesIs 
would not account for the observation that PBMC from some nor-
mal subjects demonstrated an increased precursor frequency to syn-
thetic peptides encoded by BP AG 1. 
The demonstration of an increased PBMC frequency of response 
in patients with BP to synthetic peptides encoded by the amino end 
of the coiled-coil region is also intriguing in view of recent studies 
identifying a region of sequence homology with a 60-kD heat-
shock protein (HSP) in this region ofBPAG1 [27] . HSP and mole-
cules with HSP sequence homology have been recognized recently 
as frequent targets of autoimmun~ processes [28]. The mechanisms 
by which HSP and molecules wIth HSP sequence homology be-
come targets of autoimmune processes are unknown. 
The identification of an increased PBMC response in both pa-
tients with BP and in some normal subjects against synthetic pep-
tides encoded by some regions ofBPAG 1 suggests that the presence 
ofT cells that proliferate in the presence of some regions ofBPAG 1 
may not be sufficient.in all cases to stimulate the development of 
autoantibody production. Other factors, such as the phenotype of 
the responding cells or the pattern of cytokine production in re-
sponse to antigen stimulation, may be critical in determining the 
host response to T-cell receptor engagement [29,30]. One could 
speculate that an increased PBMC precursor frequency to BPAG1 
peptides observed in some normal subjects may identify subjects at 
risk for the development ofBP at some later time. Alternatively, the 
presence of an increased precursor frequency to synthetic pep tides 
encoded within this region in some normal patients may be relevant 
in either tolerance or clearance of BP AG 1 during epidermal turn-
over. Further investigations employing larger numbers of patients, 
characterizing the phenotype of the responding cell in both patients 
with BP and controls, and determining the pattern of cytokine 
productio.n a.fter PBMC ~ctivation may. resolve these differences 
and identify Immunodomll1ant T-cell epltopes on BP AG 1. 
In summary, PBMC from 70% of patients with BP and 30% of 
normal subjects demonstrate an increased frequency of response 
when cultured with synthetic pep tides encoded by amphipathic 
regions of the BPAG 1, and in particular to those pep tides encoded 
near regions of the molecule associated with antibody activity. The 
presence of ~n increased PBMC respo?-se in. patients with BP was 
associated WIth the presence of generaltzed dIsease and the presence 
of active disease for longer than 6 weeks. 
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